SAB Biotherapeutics, Inc. SABS
At closeNov 6, 2026, 4:01 PM EST
After hours · Nov 6, 4:01 PM ET
- YTD
- -18.98%
- 1 year
- -2.26%
- Market cap
- 275.69M
- Revenue (ttm)
- 1.51M
- EPS (ttm)
- -1.35
- Shares out
- 9.23M
- Forward P/E
- -1.56
- YTD return
- -18.98%
- 1-year return
- -2.26%
- Volume
- 300.61K
- Avg volume
- 538.59K
- Open
- 2.98
- Previous close
- 2.94
- Day's range
- 2.91 – 3.14
- 52-week range
- 2.49 – 4.59
- Beta
- 0.64
- Price target
- 12.40 (+309.2%)
- Earnings date
- Aug 8, 2024
5D -0.32 (-9.55%)
Key statistics
- Enterprise value
- 17.04M
- PEG ratio
- 0.00
- Price / sales
- 26.11
- Price / book
- 1.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -26.31M
- Total cash
- 30.40M
- Total debt
- 4.52M
- Return on equity
- -174.73%
- Short % of float
- 1.41%
- 50-day average
- 3.29
- 200-day average
- 3.35
Analyst view
- Target (low)
- 6.00
- Target (mean)
- 12.40
- Target (high)
- 25.00
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -1.21.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.07 | -1.12 | -0.05 | -4.67% |
| Aug 8, 2024 | Jun 1, 2024 | -1.13 | -0.79 | +0.34 | +30.09% |
| Aug 8, 2024 | Jun 1, 2024 | -1.13 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.98 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.98 | -0.54 | +0.44 | +44.90% |
| Apr 1, 2024 | Dec 1, 2023 | -0.64 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 9, 2024 | Craig-Hallum | init | — | Buy |
| Sep 12, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Sep 9, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 28, 2024 | Oppenheimer | init | — | Outperform |
| Aug 12, 2024 | Chardan Capital | main | Buy | Buy |
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sabbiotherapeutics.com
News
12 Health Care Stocks Moving In Friday's After-Market Session 
SAB Biotherapeutics Q3 2026 Earnings Call Transcript 
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights 
FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes 
SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 Diabetes 
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13 
Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16 
12 Health Care Stocks Moving In Monday's Intraday Session 
Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday 
Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12
Your note
Sign in to keep a note on SABS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELLIAS HELEN K | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
| KING MICHAEL | Chief Financial Officer | Purchase | Nov 29, 2023 | 5,000 |
| KROPOTOVA ALEXANDRA | Officer | Stock Award(Grant) | Mar 13, 2023 | 275,000 |
| MOIN ANDREW D. | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
| REICH SAMUEL J. | Officer and Director | Purchase | Nov 28, 2023 | 766,699 |
| SESSA CAPITAL MASTER, L.P. | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.94% | 917,826 | 3.93M | Sep 29, 2024 |
| RTW Investments LP | 6.88% | 635,276 | 2.72M | Sep 29, 2024 |
| Marshall Wace LLP | 4.98% | 459,168 | 1.97M | Sep 29, 2024 |
| Sessa Capital IM, L.P. | 4.97% | 458,457 | 1.96M | Sep 29, 2024 |
| Vanguard Group Inc | 2.99% | 276,336 | 1.18M | Sep 29, 2024 |
| HB Wealth Management, LLC | 1.18% | 108,600 | 464.81K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.52% | 232,567 | 995.39K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.46% | 42,636 | 182.48K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 41,315 | 176.83K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 14,370 | 61.50K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 12,940 | 55.38K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 9,834 | 42.09K | Oct 30, 2024 |